Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Supernus Pharmaceuticals ( (SUPN) ) has issued an update.
On June 16, 2025, Supernus Pharmaceuticals held its annual stockholders meeting, where key decisions were made regarding the election of directors, executive compensation, and the appointment of KPMG LLP as the independent public accounting firm for 2025. These decisions are expected to influence the company’s governance and financial oversight, impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals’ strong financial position and strategic acquisition are significant positives. However, technical indicators suggest neutral momentum, and valuation is moderate. Challenges include declines in legacy products and patent disputes, which temper the overall outlook.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of products for the treatment of central nervous system diseases.
Average Trading Volume: 524,056
Technical Sentiment Signal: Buy
Current Market Cap: $1.82B
Learn more about SUPN stock on TipRanks’ Stock Analysis page.